Back to Search Start Over

Scope and Consistency of Outcomes Reported in Trials of Patients With Systemic Sclerosis

Authors :
Allison Tong
Daniel Sumpton
Vivek Thakkar
Jonathan C. Craig
Adrien Bigot
Bénédicte Sautenet
Geraldine Hassett
Peter Tugwell
MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE)
Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
Université de Nantes (UN)-Université de Nantes (UN)
Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
Source :
Arthritis Care & Research, Arthritis Care & Research, 2019, ⟨10.1002/acr.24027⟩
Publication Year :
2019

Abstract

International audience; OBJECTIVE: The core outcome set for trials in systemic sclerosis (SSc) was developed in 2008 and comprises eleven domains and thirty-one measures, leading to the development of a composite index (CRISS). We aimed to assess the scope, and consistency of outcomes reported in trials of SSc, and the uptake of this core set and CRISS. METHODS: MEDLINE, Cochrane CENTRAL, Embase and clinicaltrials gov were searched to identify randomized trials published from 2000 to 29 April 2018 in adults with limited or diffuse SSc. Outcomes and measures were recorded for each trial, classified into domains and the frequency of outcomes before after publication of the publication of the core set calculated. RESULTS: From 152 trials, 4193 outcomes were classified into 84 domains. The three most common domains were health-related quality of life and function (59%, 130 measures), skin (47%, 59 measures) and pulmonary (45%, 168 measures). After the publication of the core outcome set, no trial reported the complete core set with adherence to each of the eleven domains ranging from 6.1% to 54.4% and adherence to each of the thirty-one measures ranging from 0 to 48.1%. The five measures required for CRISS were reported completely in 11% of trials. CONCLUSION: Despite recognition that uniform acquisition and reporting of outcomes would enable a better evaluation of proposed SSc therapeutics, the outcome domains and measures reported in randomized trials in systemic sclerosis remain very inconsistent, with little impact of the core outcome set. This article is protected by copyright. All rights reserved.

Details

ISSN :
21514658
Volume :
72
Issue :
10
Database :
OpenAIRE
Journal :
Arthritis careresearchReferences
Accession number :
edsair.doi.dedup.....da1e9cbca9213e135b94164cab46d139
Full Text :
https://doi.org/10.1002/acr.24027⟩